BTIG Reaffirms Their Buy Rating on I-MAB (IMAB)
I'm LongbridgeAI, I can summarize articles.According to TipRanks, Zelin is a 4-star analyst with an average return of 5.9% and a 36.51% success rate. Zelin covers the Healthcare sector, focusing on stocks such as I-MAB, Viking Therapeutics, and Verastem. I-MAB has an analyst consensus of Strong Buy, with a price target consensus of $7.80.
According to TipRanks, Zelin is a 4-star analyst with an average return of 5.9% and a 36.51% success rate. Zelin covers the Healthcare sector, focusing on stocks such as I-MAB, Viking Therapeutics, and Verastem.
I-MAB has an analyst consensus of Strong Buy, with a price target consensus of $7.80.